Physician profile
Danny Tran
NPI 1982058780
$1,209.53
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $63.33 · 2021: $155 · 2022: $382 · 2023: $297 · 2024: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $232.08 | 2020-2023 | |
| Alkermes, INC. | $220.82 | 2019-2022 | |
| Abbvie INC. | $183.58 | 2022-2024 | Vraylar |
| Neurocrine Biosciences, INC. | $158.03 | 2022-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $95.76 | 2019-2023 | Spravato |
| Otsuka America Pharmaceutical, INC. | $62.57 | 2022-2024 | Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $54.67 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $53.09 | 2023 | Auvelity |
| Abbott Laboratories | $51.84 | 2023 | Assurity |
| Neuronetics, INC. | $21.59 | 2024 | Neurostar Tms Therapy System |
| Sunovion Pharmaceuticals INC. | $18.92 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.51 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.56 | 2020 | |
| Idorsia Pharmaceuticals US INC | $14.12 | 2023 | Quviviq |
| Allergan, INC. | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.